FIRST-IN-CLASS PIPELINE

RORβ: A Novel Target with Therapeutic Potential in CNS, Retinal Disease and Oncology

Orphagen is a leader in exploring the potential of the orphan nuclear receptor retinoid-related orphan receptor beta (RORβ) in diverse therapeutic areas. Our antagonists are active in preclinical models, and we are open to collaborations to investigate the properties of RORβ ligands.

We have successfully identified potent ligands for RORβ, including both antagonists and agonists. Our research has encompassed both in vitro and in vivo pharmacology. We show that ROR antagonists can modulate gene expression, as evidenced in our studies involving the retina and a small cell lung carcinoma (SCLC) cell line.

Based on genomic findings, the therapeutic potential of RORβ antagonists spans additional domains including circadian rhythm or mood.

At Orphagen, our commitment to the hunt for novel targeted therapies is embodied in our exploration of RORβ antagonist pharmacology.